News and Press Releases
Celonic Inaugurates “Next Generation” Biologics Development Centre (BDC) and Pilot Plant in Basel, Switzerland
The Celonic Group, a “Pure Play” Biologics contract development and manufacturing organisation (CDMO), expands process development and optimisation services in Basel Investment builds on “Next Generation” bioprocessing capability and pilot...
Category: BioManufacturing, Pharmaceutical
Posted: June 18, 2024
Sustainability focused PET film producer launches Evercare brand for the healthcare packaging market
18 June 2024 -- Portalegre, Portugal -- Evertis launches Evercare brand, set to be a leading provider of specialty and innovative medical-grade films designed to provide superior performance and support...
Category: Manufacturing and Packing, Other
Posted: June 18, 2024
Pharmaceutical Powerhouse: Johnson & Johnson
is once again the world's most valuable and strongest pharma brand New data from Brand Finance reveals impact of restructuring and M&A activity on brand values across the Healthcare Sector...
Category: BioManufacturing, Biotechnology, Other
Posted: June 18, 2024
A lightning-fast response – Faller Packaging produces folding boxes in record time for pharmaceutical manufacturer Pohl-Boskamp
28 May 2024 -- Waldkirch, Germany -- Pharmaceutical manufacturer G Pohl-Boskamp urgently needed packaging materials for its main product Gelomyrtol. Faller Packaging helped the company to keep its remedy for...
Category: Manufacturing and Packing, Pharmaceutical
Posted: June 18, 2024
NXI Therapeutics Extends Pre-Seed Financing to ₣3.5M in Run-up to Larger Seed Financing
Kickfund joins group of investors including JFG Life Sciences Foundation, BaseLaunch and Venture Kick 18 June 2024 -- Basel, Switzerland -- NXI Therapeutics AG, developer of tomorrow’s disruptive immunotherapies by coronin...
Category: Biotechnology, Drug Discovery, Other
Posted: June 18, 2024
Primrose Bio Announces Investment from 1315 Capital to Advance Manufacturing Solutions for Next-Generation Therapeutics
June 17 2024 - California, US – Primrose Bio, Inc. (“Primrose,” the “company”), a company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in...
Category: Biotechnology, Drug Delivery, Other
Posted: June 18, 2024
Primrose Bio, 10790 Roselle Street, San Diego, CA 92121 United States
Life Sciences organizations expect more than one-fifth of revenue to come from connected health in the next five years
Sixfold increase in biopharma organizations with market-ready connected health products since 2021; three in four medtech organizations already have connected health products on the market June 18 2024 - Paris,...
Category: Biotechnology, Other
Posted: June 18, 2024
Basecamp Research launches ZymCTRL a world-first, open source, generative AI tool that designs enzymes for more sustainable industrial processes. ZymCTRL is the world’s first open-source, text-based enzyme generation model and can be used across multiple industries, including therapeutics and sustainability initiatives.
AI model able to produce sequences that produced functional enzymes with desirable characteristicsfor industrial applications. Basecamp Research field scientists collect samples during an expedition to Costa Rica on July 29,...
Category: BioManufacturing, Drug Delivery, Drug Discovery, Other
Posted: June 18, 2024
Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for Services to Healthcare Innovation and Delivery
Ground-breaking discoveries on the characteristics of RNA epigenetics unveiled novel targets to treat diseases 17 June 2024, Cambridge, UK - STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 17, 2024
Achema launch: new Settle Plate Changer from Syntegon for automated viable monitoring
Syntegon launches patented new development for the pharmaceutical industry Focus on Annex 1 compliance: reducing machine stops, manual intervention, and contamination risks in the aseptic filling process. Seamless and sustainable...
Category: Manufacturing and Packing, Pharmaceutical
Posted: June 17, 2024
SGD Pharma releases its latest sustainability report underscoring its global commitment to the highest environmental, social and governance standards
12 June 2024, Paris La Défense, France – SGD Pharma, global leader in glass pharmaceutical packaging, has published its latest 2023 Corporate Social Responsibility (CSR) report illustrating the sustainable practices...
Category: Manufacturing and Packing, Pharmaceutical
Posted: June 17, 2024
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of 8.9...
Category: Drug Discovery
Posted: June 17, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Enterprise Therapeutics appoints Dr Renu Gupta as chief medical officer and Dr Janet Hammond as non-executive director
Appointments bring additional respiratory and late clinical-stage drug development experience as company commences Phase 2a clinical trial of its lead asset 17 June 2024, Brighton, UK -: Enterprise Therapeutics Ltd...
Category: Biotechnology, Pharmaceutical
Posted: June 17, 2024
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK
TALVEY (talquetamab) demonstrated highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
24-month overall survival rate of 67% achieved with talquetamab 0.8mg/kg biweekly dosing in the phase 1/2 MonumenTAL-1 study 14 June 2024 – Beerse, Belgium – Janssen-Cilag International NV, a Johnson...
Category: Biotechnology, Drug Discovery
Posted: June 17, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Updated phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed-duration IMBRUVICA (ibrutinib) plus venetoclax as first-line treatment for patients with chronic lymphocytic leukaemia, including those with high-risk disease
At 5 years, 67% of patients were progression-free, with overall survival at 96% for all treated patients 14 June 2024 – Beerse, Belgium – (GLOBE NEWSWIRE) – Janssen-Cilag International NV,...
Category: Biotechnology, Drug Discovery
Posted: June 17, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
